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In the present work, we focused on the study of pharmacokinetic interactions of 
cyclin-dependent kinase inhibitors (CDKi) with drug efflux transporters breast cancer 
resistance protein (BCRP) and P-glycoprotein (P-gp). Using accumulation and transport 
methods with MDCKII-ABCG2 cells, we showed purvalanol A, olomoucine II, 
bohemine and roscovitine to inhibit BCRP. Employing accumulation method with 
MDCKII-ABCB1 cells, we further observed that purvalanol A potently inhibits P-gp 
and partial inhibition was recorded in the case of other studied CDKi (olomoucine II, 
roscovitine, flavopiridol, SNS-032). Transport method with the same cellular models 
was used for the study of substrate affinity of olomoucine II and purvalanol A when 
olomoucine II was determined to be a dual P-gp and BCRP substrate. Substrate affinity 
of purvalanol A toward any of the transporters tested was not observed. These findings 
were confirmed by the ATPase vesicular assay and using this experimental setup, we 
further showed that roscovitine is a P-gp substrate. Flavopiridol and SNS-032 seem to 
lack substrate affinity toward P-gp or to be P-gp substrates with a very low affinity. In 
the following part of this work we verified our in vitro results at organ level employing 
the method of dually perfused rat term placenta. We confirmed inhibition of the rat Bcrp 
by purvalanol A, olomoucine II, bohemine and roscovitine and substrate affinity of 
olomoucine II toward the rat P-gp as well as Bcrp. At the same time, we excluded the 
substrate affinity of purvalanol A toward both examined transporters. In the final part of 
the study, we tested our hypothesis that CDKi, which inhibit drug transporters, may 
increase the accumulation of concomitantly administered cytotoxic substrates and, at the 
same time, potentiate their effect by their own antiproliferative and cytotoxic activity. 
Combination index method of Chou-Talalay was employed for this purpose. Synergistic 
or at least additive effects were observed in the combinations of olomoucine II or 
purvalanol A with mitoxantrone, an established BCRP substrate, in three cell lines 
which express considerable amounts of BCRP. Our hypothesis was further confirmed in 
the combinations of purvalanol A, roscovitine or olomoucine II with daunorubicin (P-gp 
substrate) when significantly higher synergistic effects of these combinations were 
observed in MDCKII-ABCB1 cells in comparison with parent cells. In the light of our 
results, it is possible to expect considerable impact of tested CDKi on the 
pharmacokinetic as well as pharmacodynamic behavior of concomitantly administered 
drugs, which are BCRP or P-gp substrates. This fact should be kept in mind in the case 
of possible introduction of CDKi into the clinical area. Our approach combining CDKi, 
which inhibit drug transporters, with the cytotoxic substrates of these transporters could, 
at least partially, help overcome the multidrug resistance which constitutes one of the 
main limitations in chemotherapy. 
 
